 Those
receiving full-dose anticoagulation received a longer
course of treatment and all patients were followed for
3 months. There was no difference in the incidence of
VTE or recurrent SVT between the groups or in the safety
outcomes of major bleeding or clinically nonmajor
bleeding. The authors concluded that these ﬁndings
are hypothesis generating and support a trial evaluating
the efﬁcacy of preventative dose anticoagulation in

comparison with therapeutic